Danaher Corporation has announced a collaboration with AstraZeneca for diagnostic tools and tests development and ...

New research has shown that the ArteraAI test can help identify which men with non-metastatic high-risk prostate cancer are ...

Acclaro Medical has completed a Series B funding round, raising $23m, to spur the growth of its flagship products, UltraClear ...

Moximed has announced the treatment of the first subject in the MOTION randomised controlled trial (RCT) assessing its MISHA ...

HistoSonics' Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet ...

Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.

Illumina is expanding access to its oncology range of IVD tests, as its TruSight Oncology Comprehensive IVD is now covered ...

BD is set to commence a multi-centre registry study, XTRACT, of the Rotarex Atherectomy System, for peripheral artery disease ...

The CEO of Flow Neuroscience has called out the US Food and Drug Administration (FDA) for market entry delays for clinically ...

The FDA has granted 510(k) clearance for Distalmotion’s DEXTER robotic surgery system to be used in adult cholecystectomies.

SAGA Diagnostics has commercially launched the multi-cancer molecular residual disease (MRD) platform, Pathlight, in the US.

NeuroPace has reported the initial primary endpoint one-year outcomes from the NAUTILUS trial of the RNS System.